Andrew Witty news from FiercePharma
News
Pharma CEOs mull industry "trust deficit'
We love it when pharma CEOs depart from their usual talking points about financial results and restructurings and pipelines, to wax philosophical on their place in the word. This week, we heard an Read more...
GSK CEO also-rans may get on board
Last week, the buzz about GlaxoSmithKline's CEO-presumptive Andrew Witty included worries that his Read more...
Just who is Glaxo's Andrew Witty?
If yesterday was Andrew Witty's debut as heir apparent to the GlaxoSmithKline CEO suite, then today is the morning-after gossip session about Read more...
GSK taps Witty as next CEO
It's a changing of the guard--in more ways than one. GlaxoSmithKline has appointed Andrew Witty (photo), Read more...
Get more Andrew Witty coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight